(Q40712492)

English

Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).

scientific article published on February 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 September 2017

Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). (English)

1 reference

Europe PubMed Central

23 September 2017

autotransplantation

1 reference

based on heuristic

inferred from title

author name string

Lazarus HM

1

1 reference

Europe PubMed Central

23 September 2017

Loberiza FR Jr

2

1 reference

Europe PubMed Central

23 September 2017

Zhang MJ

3

1 reference

Europe PubMed Central

23 September 2017

Armitage JO

4

1 reference

Europe PubMed Central

23 September 2017

Ballen KK

5

1 reference

Europe PubMed Central

23 September 2017

Bashey A

6

1 reference

Europe PubMed Central

23 September 2017

Bolwell BJ

7

1 reference

Europe PubMed Central

23 September 2017

Burns LJ

8

1 reference

Europe PubMed Central

23 September 2017

Freytes CO

9

1 reference

Europe PubMed Central

23 September 2017

Gale RP

10

1 reference

Europe PubMed Central

23 September 2017

Gibson J

11

1 reference

Europe PubMed Central

23 September 2017

Herzig RH

12

1 reference

Europe PubMed Central

23 September 2017

LeMaistre CF

13

1 reference

Europe PubMed Central

23 September 2017

Marks D

14

1 reference

Europe PubMed Central

23 September 2017

Mason J

15

1 reference

Europe PubMed Central

23 September 2017

Miller AM

16

1 reference

Europe PubMed Central

23 September 2017

Milone GA

17

1 reference

Europe PubMed Central

23 September 2017

Pavlovsky S

18

1 reference

Europe PubMed Central

23 September 2017

Reece DE

19

1 reference

Europe PubMed Central

23 September 2017

Rizzo JD

20

1 reference

Europe PubMed Central

23 September 2017

van Besien K

21

1 reference

Europe PubMed Central

23 September 2017

Vose JM

22

1 reference

Europe PubMed Central

23 September 2017

Horowitz MM

23

1 reference

Europe PubMed Central

23 September 2017

language of work or name

0 references

publication date

1 February 2001

1 reference

Europe PubMed Central

23 September 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

23 September 2017

27

1 reference

Europe PubMed Central

23 September 2017

4

1 reference

Europe PubMed Central

23 September 2017

387-396

1 reference

Europe PubMed Central

23 September 2017

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1702796

0 references

Cancer statistics, 1998.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

Phase II study of MOPLACE chemotherapy for patients with previously treated Hodgkin's disease: a CALGB study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

Is there an effective salvage therapy for advanced Hodgkin's disease?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

21 January 2018

Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curi

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of CAV regimen (CCNU, Melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): comparative results with two CBV regimens and importance of disease status at transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

Progressive disease after ABMT for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of immunotoxins for potential clinical use in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702796

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1702796

1 reference

Europe PubMed Central

23 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

23 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40712492&oldid=1504490011"